Comparative Pharmacology
Head-to-head clinical analysis: CETACORT versus TEMOVATE E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETACORT versus TEMOVATE E.
CETACORT vs TEMOVATE E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; binds to glucocorticoid receptors, modulating gene transcription and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
1-2 drops or 0.5-1 cm ribbon applied to affected eye(s) 3-4 times daily; for severe inflammation, every 1-2 hours initially. Ophthalmic suspension (0.5% prednisolone acetate) or ointment (0.25% prednisolone acetate).
Apply a thin layer to the affected skin areas once daily. Not for use for more than 2 consecutive weeks. Use no more than 50 g per week. Not for use in children under 12 years.
None Documented
None Documented
Terminal half-life: 3.5 hours; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: approximately 1.5-3 hours (topical application). Clobetasol propionate is rapidly cleared, minimizing systemic accumulation with short-term use.
Renal: 95% as unchanged drug; biliary/fecal: <5%
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for a minor fraction.
Category C
Category C
Topical corticosteroid
Topical corticosteroid